Core Viewpoint - NovaBridge Biosciences has appointed Dr. Emmett T. Cunningham, Jr. as Vice Chairman of the Board, which is expected to enhance the company's strategic direction and shareholder value through his extensive biopharma experience [1][3][7]. Company Overview - NovaBridge is a global biotechnology platform focused on accelerating access to innovative medicines, combining business development expertise with agile clinical development to advance breakthrough assets [9]. - The company operates a unique hub-and-spoke business model aimed at bridging the gap between unmet patient needs and transformative care [3][7]. Leadership Appointment - Dr. Cunningham brings over 25 years of experience in biopharma, having held leadership roles in venture capital and major pharmaceutical companies, including Blackstone Group and Pfizer [2][5][6]. - His appointment is seen as a positive endorsement of NovaBridge's mission to create shareholder value by expediting the development of transformative medicines [7]. Research and Development Focus - Dr. Cunningham will also join the Research and Development Committee of the Board, which is established to expedite innovation and long-term growth [7]. - The company is currently developing several drug candidates, including givastomig and VIS-101, targeting various cancers and eye diseases [10][12]. Pipeline Highlights - Givastomig is a bispecific antibody being evaluated in a Phase 2 study for Claudin 18.2-positive gastric cancer, following positive results from a Phase 1b study [11]. - VIS-101 is in a Phase 2a study for wet age-related macular degeneration and diabetic macular edema, aiming to provide more durable treatment benefits [12].

Core Insights - NovaBridge Biosciences has initiated a global Phase 2 randomized study for givastomig, a bispecific antibody targeting Claudin 18.2, in combination with nivolumab and chemotherapy for HER2-negative metastatic gastric cancer [1][2][3] - The Phase 1b results demonstrated a 75% objective response rate (ORR) and a median progression-free survival (mPFS) of 16.9 months, indicating strong efficacy and potential for givastomig to become a best-in-class therapy [3][4][5] - The gastric cancer market is projected to reach $12 billion by 2030, highlighting significant commercial potential for givastomig [1][3] Study Details - The Phase 2 study will enroll approximately 180 patients and aims to confirm the efficacy and safety of givastomig in a broader patient population [5] - Primary endpoint is progression-free survival (PFS), with secondary endpoints including ORR, overall survival (OS), duration of response (DoR), and disease control rate (DCR) [5] Clinical Data - Phase 1b data showed that patients treated with givastomig at 8 mg/kg and 12 mg/kg had an ORR of 77% and 73% respectively, with durable responses and good tolerability [4][3] - The study's results are expected to be presented in 2027, with updated Phase 1b results anticipated in the second half of 2026 [2][3] Product Overview - Givastomig is designed to activate T cells in the tumor microenvironment, targeting Claudin 18.2-positive tumor cells, and is being developed for gastric and other gastrointestinal cancers [7][11] - The product is being developed in partnership with ABL Bio, with NovaBridge holding worldwide rights outside of Greater China and South Korea [8]

Core Insights - Fu Wei, Executive Chairman of NovaBridge Biosciences, intends to purchase up to $5,000,000 of the Company's American Depository Shares (ADSs) in open market transactions, starting from January 15, 2026 [1] - The Company has executed a new business strategy in 2025, which has positioned it for growth, supported by positive Phase 1b dose expansion data for its drug candidate, givastomig [2][3] Company Overview - NovaBridge is a global biotechnology platform focused on accelerating access to innovative medicines, combining business development expertise with clinical development to advance breakthrough assets [4] - The Company’s pipeline includes givastomig, a bispecific antibody targeting Claudin 18.2, and VIS-101, a bifunctional biologic targeting VEGF-A and ANG2 [5] Drug Development - Givastomig is designed to treat Claudin 18.2-positive gastric cancer and is currently in clinical development [6] - VIS-101 is completing a Phase 2 study for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) [7]

Core Viewpoint - NovaBridge Biosciences has been included in the Nasdaq Biotech Index, highlighting its status as an industry leader and enhancing its visibility in the biotechnology sector [3][8]. Company Overview - NovaBridge is a global biotechnology platform focused on accelerating access to innovative medicines by combining business development expertise with agile clinical development [3]. - The company aims to bridge science, strategy, and execution to advance transformative therapies from discovery to patients [3]. Key Developments - Fu Wei, Executive Chairman, and Sean Fu, CEO, will ring the Nasdaq Opening Bell on January 2, 2026, marking a significant milestone for the company [2][9]. - The inclusion in the Nasdaq Biotech Index became effective on December 19, 2025, which is seen as a validation of NovaBridge's strategic vision and pipeline [3][8]. Product Pipeline - The leading product in NovaBridge's pipeline is givastomig, a bispecific antibody targeting Claudin 18.2, aimed at treating gastric cancer and other gastrointestinal malignancies [4][5]. - VIS-101, another key product, targets VEGF-A and ANG-2 for treating wet age-related macular degeneration and diabetic macular edema, currently in a Phase 2 study [6]. Strategic Collaborations - NovaBridge is collaborating with ABL Bio on ragistomig, a bispecific antibody designed for solid tumors, and holds worldwide rights outside of China for uliledlimab, an anti-CD73 antibody [5].

Core Insights - NovaBridge Biosciences announced new data from the Phase 1 dosing study of ragistomig, a bispecific 4-1BB X PD-L1 antibody, showing consistent antitumor activity and improved safety profile with a new dosing schedule [1][2][3] Group 1: Study Results - The new Q6W dosing schedule demonstrated a disease control rate (DCR) of 58.8%, comparable to the 64.3% DCR observed with the previous Q2W schedule [7] - Only 5% of patients experienced Grade ≥3 liver function test (LFT) elevations with the Q6W regimen, compared to 40% with the Q2W regimen [13] - The study achieved its objective of extending the therapeutic window, supporting the advancement of ragistomig into combination studies [2][3] Group 2: Immunological Data - The Q6W dosing showed positive immunological data, including expansion of effector memory and CD8+ T cells, indicating durable immune engagement [7][13] - The study reported no cases of cytokine release syndrome (CRS) with either dosing schedule, highlighting the favorable safety profile [7][13] Group 3: Patient Characteristics - The study included 20 heavily pre-treated subjects receiving 3 mg/kg Q6W ragistomig, with 100% previously treated with immuno-oncology therapies [12] - Among the 17 evaluable patients on the Q6W regimen, the objective response rate was 11.8%, while the Q2W regimen had a 28.6% response rate [9] Group 4: Future Directions - The ongoing evaluation of the 5 mg/kg Q6W dosing cohort and future combination studies is anticipated to further assess the efficacy of ragistomig [8]

Core Insights - NovaBridge Biosciences announced new data from the expanded Phase 1 dosing study for ragistomig, a bispecific antibody targeting 4-1BB and PD-L1, to be presented at ESMO-IO 2025 [1][2] - The study successfully extended the therapeutic window for ragistomig, demonstrating strong anti-tumor efficacy and improved tolerability, including enhanced hepatic safety [2][3] - Ragistomig aims to provide new treatment options for patients resistant to checkpoint inhibitors, a significant drug class in cancer therapy [3][5] Company Overview - NovaBridge is a global biotechnology platform focused on accelerating access to innovative medicines, combining business development expertise with clinical development [8] - The company is developing a differentiated pipeline, including ragistomig and givastomig, targeting various cancers and conditions [8][9] - Ragistomig is being developed in collaboration with ABL Bio, utilizing advanced bispecific antibody technology to minimize off-tumor toxicity [5][6] Clinical Study Details - The Phase 1 study of ragistomig is ongoing in the U.S. and South Korea, with a primary focus on defining dose-limiting toxicity and adverse event profiles [5][6] - The new dosing schedule, Q6W, has shown promising results in PD-L1 non-responders, balancing safety and sustained efficacy [6][7] - Interim results, including immunological data, are expected to be presented at the upcoming ESMO-IO meeting [6][7]

Core Insights - NovaBridge Biosciences announced the appointment of Dr. Cadmus C. Rich as Chief Medical Officer and Dr. Carlos Quezada-Ruiz as Chairman of the Scientific Advisory Board for its subsidiary Visara, Inc. [1][2][3] Company Developments - The appointments of Dr. Rich and Dr. Quezada-Ruiz highlight Visara's commitment to developing innovative ophthalmic therapies, particularly the VIS-101 program targeting wet age-related macular degeneration (wet AMD) [2][5][12] - Dr. Rich aims to accelerate the development of new ophthalmology treatments and is focused on completing the Phase 2 study of VIS-101 [2][12] - Dr. Quezada-Ruiz brings extensive experience in retinal therapies and emphasizes the need for more durable treatment options for retinal diseases [2][10] Product Pipeline - VIS-101 is a bifunctional biologic targeting VEGF-A and ANG-2, with potential applications in wet AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO) [5][12][17] - The drug is expected to be Phase 3-ready in 2026, following the completion of its current Phase 2 study [5][12] Leadership Expertise - Dr. Rich has a strong background in ophthalmology and drug development, having previously held leadership roles in various biopharmaceutical companies [4][6][7] - Dr. Quezada-Ruiz has significant experience in the global development of retinal therapies and has held senior positions at major pharmaceutical companies [8][9][10] Strategic Vision - The appointments are part of NovaBridge's strategic transformation into a global biotech platform, showcasing its ability to attract top-tier talent in the industry [3][5] - The company aims to deliver value to shareholders through its innovative "hub-and-spoke" strategy [3]

Core Insights - NovaBridge Biosciences announced the appointment of Dr. Cadmus C. Rich as Chief Medical Officer and Dr. Carlos Quezada-Ruiz as Chairman of the Scientific Advisory Board for its subsidiary Visara, Inc. [1][2][3] Leadership Appointments - Dr. Rich and Dr. Quezada-Ruiz are recognized leaders in ophthalmology and drug development, enhancing Visara's capabilities in clinical functions and scientific advisory [2][5] - Dr. Rich aims to accelerate the development of innovative ophthalmology treatments, particularly focusing on the VIS-101 program [2][12] - Dr. Quezada-Ruiz has extensive experience in developing retinal therapies and is committed to advancing VIS-101 into registrational development [2][10] VIS-101 Program - VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2, with potential applications in treating wet AMD, DME, and RVO [5][12] - The program is expected to be Phase 3-ready by 2026, following the completion of a Phase 2 study [5][12] - The dual targeting mechanism of VIS-101 is anticipated to provide more durable treatment benefits compared to current standards of care [12][18] Strategic Transformation - The appointments of Dr. Rich and Dr. Quezada-Ruiz reflect NovaBridge's strategic transformation into a global biotech platform and its commitment to delivering shareholder value [3][5] - The ability to attract distinguished leaders underscores the potential of VIS-101 and the company's innovative "hub-and-spoke" strategy [3][5] Company Overview - Visara, Inc. is focused on developing best-in-class ophthalmic therapeutics and is majority-owned by NovaBridge, which controls global rights to VIS-101 outside of Greater China [13][18] - NovaBridge is dedicated to accelerating access to innovative medicines through a combination of business development expertise and agile clinical development [15][16]

Core Insights - NovaBridge Biosciences is focused on developing immuno-oncology agents for cancer treatment, with several projects in various clinical trial stages [1] - The company has strategic partnerships with industry leaders, enhancing its research and development capabilities [1] Price Target Changes - The consensus price target for NovaBridge's stock has decreased from $7.75 to $7.00, indicating a shift in analyst sentiment [2][5] - This decline in price target suggests potential influences from recent developments or broader market conditions affecting the biotech sector [2] Investment Considerations - Investors should monitor NovaBridge's ongoing clinical trials and strategic partnerships, as these factors could significantly impact future performance and stock valuation [3][5] - New announcements or updates from NovaBridge may provide further insights into potential stock movements [3] Comparative Analysis - In contrast, IMab has received a positive outlook from analysts, with a price target set at $8, reflecting increased optimism about its earnings prospects [4] - This comparison highlights the importance of analyst ratings and price targets in assessing biotech stocks [4][5]

Core Insights - NovaBridge Biosciences is focused on developing immuno-oncology agents for cancer treatment, with several projects in various clinical trial stages [1] - The company has established strategic partnerships with major players in the industry to enhance its research and development efforts [1] Price Target Analysis - The consensus price target for NovaBridge's stock has decreased from $7.75 to $7.00 over the past month, indicating a more cautious short-term outlook from analysts [2][5] - Despite the recent decrease, the price target has remained stable over the past year, suggesting a consistent long-term view of the company's potential [2] Comparative Analysis with IMab - IMab has been upgraded to a Zacks Rank 2 (Buy), with a new price target of $8 set by analyst Kumaraguru Raja, reflecting increased optimism about its earnings potential [3][5] - The contrasting outlooks for NovaBridge and IMab highlight varied analyst sentiments based on recent developments in the biotech sector [4][5]